Mauro Loi
@isteddos
Followers
475
Following
7K
Statuses
3K
Joined October 2016
Hora Est! So grateful to Erasmus MC for granting me the opportunity to defend my PhD on 10/12/2024! Thanks to my beautiful paranymphs Linda Rossi and Alba Magallón Baro and promoters Prof Hoogeman and Dr Nuyttens! Thanks to all my friends for being there ❤️
2
0
18
RT @yuanjamesrao: A major advance in laser-proton devices has been reported. It can produce energies up to 6MeV at FLASH dose rates. The b…
0
1
0
RT @NiuSanford: Ph I trial of pre-op SBRT for resectable pancreas ca: R0 resection rate 100%. Vs NORPACT1 neoadjuvant chemo arm alone R0 5…
0
29
0
RT @bavilima: @ASCO #GU25 High-risk PCa ▶️ RT vs RP ▶️ IPD data from 2 trials @soumyajitroy @DrSpratticus ❗️Lower cumulative incidence of…
0
23
0
RT @jryckman3: 🚀 The SOFT trial is packed with fascinating insights! Let’s dive into the details 🧵 ⬇️ #radonc…
0
8
0
Great job u did 👍
@5_utr Lots of great studies here! Working on a presentation about this stuff now. 1y freedom from systemic therapy ~90% for RCC oligoSBRT to 1-2 lesions. Please lmk if I missed any prospective studies with these endpoints. I'll DM you full pres for feedback tmo, giving it this Wed
1
1
3
RT @TheLancet: “...to care is an act not of weakness, but of strength.” The Lancet response:
0
186
0
RT @jryckman3: Great to see more data in this space! This brings to mind a standout study, the only one I’m aware of for targets above th…
0
10
0
RT @StephenVLiu: Review in @JCOOP_ASCO on evolution of immunotherapy for #SCLC including first-line standards of care: IMpower133, CASPIAN,…
0
19
0
The experience of our team in SBRT for oligometastatic H&N: nice work @VSalvestrini @PierluigiBonomo @CarlottaB @isa
0
2
10
@jryckman3 @5_utr On the other hand, the evidence for treating relatively rare cervical esophagus SCC with higher doses was very low.. even in older versions of NCCN the only reference we got was a retrospective study by Minsky et al in the 90s.
1
0
1
RT @jryckman3: @drjamesgood @OncoThor @TheRealDoctorOs @5_utr Newer TARE techniques in DOSISPHERE focus on dose escalation to small tumor s…
0
2
0
RT @jryckman3: @UzomaMDPhD @benchallacombe @TylerSbrt @bellagharbieh @JafferUrol Interesting to see that the sections on HIFU, Cryo, and IR…
0
1
0
RT @VivekSubbiah: Evidence for a reduction in number of cycles of immune checkpoint inhibitors - The Lancet Oncology @TheLancetOncol https:…
0
5
0
RT @NiuSanford: A 33 min overview of GI rad onc! I made this video for an oral boards review course, sharing here. It’s just 5 slides (be…
0
106
0
RT @dr_yakupergun: Annual vs. less frequent mammographic surveillance in people with BC aged 50 years and older in the UK (Mammo-50) mFU:…
0
21
0
RT @PaulSargos: In press in @Annals_Oncology ⏩ The RADIOSARP trial results : a phase Ib study of olaparib with concomitant radiotherapy in…
0
4
0
RT @HenningWillers: Randomized trial out of China: Better PFS/OS for EGFR TKI + 60 Gy to primary #lungcancer & LNs but also more toxicity…
0
3
0
RT @dr_yakupergun: Meta‐analysis of randomized controlled trials of external‐beam radiation versus TACE for HCC Pooled analysis of 3 RCTs…
0
54
0
RT @RKuehnleRadOnc: Our meta-analysis comparing EBRT & TACE for HCC is here in @JournalCancer ! (Spoiler: RT benefits patients in LC and PF…
0
23
0